CO2018005752A2 - Nuevos anticuerpos anti-claudina y sus métodos de uso - Google Patents

Nuevos anticuerpos anti-claudina y sus métodos de uso

Info

Publication number
CO2018005752A2
CO2018005752A2 CONC2018/0005752A CO2018005752A CO2018005752A2 CO 2018005752 A2 CO2018005752 A2 CO 2018005752A2 CO 2018005752 A CO2018005752 A CO 2018005752A CO 2018005752 A2 CO2018005752 A2 CO 2018005752A2
Authority
CO
Colombia
Prior art keywords
methods
new anti
claudin antibodies
antibodies
claudin
Prior art date
Application number
CONC2018/0005752A
Other languages
English (en)
Inventor
Robert A Stull
Sarah Fong
Vikram Natwarsinhji Sisodiya
Samuel A Williams
Original Assignee
Abbvie Stemcentrx Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Stemcentrx Llc filed Critical Abbvie Stemcentrx Llc
Publication of CO2018005752A2 publication Critical patent/CO2018005752A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

En la presente se proveen nuevos anticuerpos y conjugados de anticuerpo y fármaco anti-CLDN (ADC), incluyendo a derivados de los mismos, y métodos para usar los mismos para tratar trastornos proliferativos.
CONC2018/0005752A 2015-12-04 2018-05-31 Nuevos anticuerpos anti-claudina y sus métodos de uso CO2018005752A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562263542P 2015-12-04 2015-12-04
US201662427027P 2016-11-28 2016-11-28
PCT/US2016/064617 WO2017096163A1 (en) 2015-12-04 2016-12-02 Novel anti-claudin antibodies and methods of use

Publications (1)

Publication Number Publication Date
CO2018005752A2 true CO2018005752A2 (es) 2018-06-12

Family

ID=58797837

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0005752A CO2018005752A2 (es) 2015-12-04 2018-05-31 Nuevos anticuerpos anti-claudina y sus métodos de uso

Country Status (23)

Country Link
US (1) US20190083645A1 (es)
EP (1) EP3383917A4 (es)
JP (1) JP2019500335A (es)
KR (1) KR20180088445A (es)
CN (1) CN108473588A (es)
AU (1) AU2016364853A1 (es)
BR (1) BR112018011319A2 (es)
CA (1) CA3006738A1 (es)
CL (2) CL2018001481A1 (es)
CO (1) CO2018005752A2 (es)
CR (1) CR20180348A (es)
DO (1) DOP2018000138A (es)
EC (1) ECSP18049762A (es)
HK (1) HK1254743A1 (es)
IL (1) IL259681A (es)
MA (1) MA43385A (es)
MX (1) MX2018006782A (es)
PE (1) PE20181302A1 (es)
PH (1) PH12018501153A1 (es)
RU (1) RU2018124319A (es)
SG (1) SG11201804673WA (es)
TW (1) TW201726175A (es)
WO (1) WO2017096163A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA40921A (fr) * 2014-11-05 2017-09-12 Abbvie Stemcentrx Llc Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation
CN109790222B (zh) 2016-07-08 2022-03-15 克莱格医学有限公司 抗密蛋白18a2的抗体及其应用
SG11202000358YA (en) * 2017-08-18 2020-02-27 Medimmune Ltd Pyrrolobenzodiazepine conjugates
JP2020532543A (ja) * 2017-09-02 2020-11-12 アッヴィ・インコーポレイテッド 抗ｅｇｆｒ抗体薬物コンジュゲート（ａｄｃ）及びその使用
SG11202001762RA (en) * 2017-09-02 2020-03-30 Abbvie Inc Anti-egfr antibody drug conjugates (adc) and uses thereof
EP3690038A4 (en) 2017-09-29 2021-05-19 Daiichi Sankyo Company, Limited ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE
WO2019224340A1 (en) * 2018-05-25 2019-11-28 Medimmune Limited Pyrrolobenzodiazepine conjugates
EA202192146A1 (ru) * 2019-02-15 2021-11-09 Интиграл Молекьюлар, Инк. Антитела к клаудину 6 и их применение
CA3134055A1 (en) * 2019-03-20 2020-09-24 The Regents Of The University Of California Claudin-6 antibodies and drug conjugates
WO2020196474A1 (ja) 2019-03-25 2020-10-01 第一三共株式会社 抗体－ピロロベンゾジアゼピン誘導体コンジュゲート
CA3160159A1 (en) 2019-11-05 2021-05-14 LaNova Medicines Limited Antibody-drug conjugates targeting claudin 18.2
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
KR102451185B1 (ko) * 2021-08-05 2022-10-07 환인제약 주식회사 도네페질 함유 지속방출형 미립구
CN114878728A (zh) * 2022-05-06 2022-08-09 浙江大学 一种新型的抗体肽图检测还原方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2425309B (en) * 2003-12-31 2008-07-09 Council Scient Ind Res C2-fluoro pyrrolo[2,1-c][1,4]benzodiazepine dimers
US7189710B2 (en) * 2004-03-30 2007-03-13 Council Of Scientific And Industrial Research C2-fluoro pyrrolo [2,1−c][1,4]benzodiazepine dimers
WO2011130613A1 (en) * 2010-04-15 2011-10-20 Seattle Genetics, Inc. Targeted pyrrolobenzodiazapine conjugates
CA2885340C (en) * 2012-10-12 2016-11-08 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
WO2014075697A1 (en) * 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
JP6515111B2 (ja) * 2013-11-06 2019-05-22 アッヴィ・ステムセントルクス・エル・エル・シー 新規の抗クローディン抗体および使用方法

Also Published As

Publication number Publication date
SG11201804673WA (en) 2018-06-28
HK1254743A1 (zh) 2019-07-26
CL2018001481A1 (es) 2018-08-24
DOP2018000138A (es) 2018-12-31
TW201726175A (zh) 2017-08-01
EP3383917A1 (en) 2018-10-10
MX2018006782A (es) 2018-11-09
CL2019000189A1 (es) 2019-06-07
PE20181302A1 (es) 2018-08-09
BR112018011319A2 (pt) 2018-12-04
PH12018501153A1 (en) 2019-01-28
IL259681A (en) 2018-07-31
US20190083645A1 (en) 2019-03-21
AU2016364853A1 (en) 2018-06-21
CN108473588A (zh) 2018-08-31
CR20180348A (es) 2018-08-23
WO2017096163A1 (en) 2017-06-08
ECSP18049762A (es) 2018-07-31
EP3383917A4 (en) 2019-08-21
JP2019500335A (ja) 2019-01-10
RU2018124319A (ru) 2020-01-09
KR20180088445A (ko) 2018-08-03
CA3006738A1 (en) 2017-06-08
MA43385A (fr) 2018-10-10

Similar Documents

Publication Publication Date Title
DOP2018000138A (es) Nuevos anticuerpos anti-claudina y sus métodos de uso
CL2019000334A1 (es) Nuevos conjugados de anticuerpo y usos de los mismos (divisional solicitud 201502357)
PE20160870A1 (es) Anticuerpos anti-claudina novedosos y metodos de uso
CL2018000595A1 (es) Anticuerpos anti-pd1 y métodos de uso
CL2017003240A1 (es) Anticuerpos anti-rnf43 novedosos y métodos para su uso
CO2018001624A2 (es) Conjugados anticuerpo anti-dll3-fármaco y métodos de uso
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
DOP2017000052A (es) Nuevos anticuerpos anti-mfi2 y metodos de uso
CY1119590T1 (el) Ρυθμιστες dll3 και μεθοδοι χρησης
UY37278A (es) Anticuerpos anti-b7-h3 y conjugados de fármaco y anticuerpos
CL2016000468A1 (es) Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso.
CO2018005433A2 (es) Conjugados de fármaco de anticuerpo her2 específicos de sitio
PH12016501109A1 (en) Novel anti-dpep3 antibodies and methods of use
ECSP17031725A (es) Receptores quiméricos de anitígeno anti-clon y métodos de uso
CO2018013298A2 (es) Anticuerpos anti-gitr y sus usos.
AR091700A1 (es) Anticuerpos e inmunoconjugados anti-cd79b
BR112016004245A2 (pt) moduladores de sez6 e métodos de uso
CO2017010692A2 (es) Construcciones de calicheamicina y sus métodos de uso
ECSP20082970A (es) Conjugados de fármaco y anticuerpo anti-sez6 y métodos de uso
AR101757A1 (es) Anticuerpos anti-mfi2 y métodos de uso